Jefferies analyst Peter Welford maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £114.00.

AstraZeneca (AZN) and Daiichi Sanyko (DSKYF)(DSNKY) said the FDA has accepted their application with priority review for ...

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

The Israeli-American unicorn company ImmunAI has signed a multi-year cooperation agreement with the pharmaceutical giant ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of the immune ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...

United Kingdom-based biopharmaceutical giant AstraZeneca will add 10 to 15 new projects to the company's research and ...

With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest ...

We recently compiled a list of 8 Cheap Growth Stocks to Buy According to Analysts. In this article, we will look at where ...